An article published 1st January 2017 in “ONCOMEDICINE” using our Annexin V kit, by our customers from Medical Clinic, Hospital Coburg, University of Wurzburg, Coburg, Germany and Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Greece, in the study of COX-2 Inhibitors, a Potential Synergistic Effect with Antineoplastic Drugs in Lung Cancer. Congrats and Thanks
Summary:
Lung cancer represents the leading cause of cancer-related deaths worldwide and novel therapeutic approaches targeting crucial pathways are urgently needed to improve its treatment. Inflammation plays a critical role in multistage tumor development and increased evidence has supported the involvement of cyclooxygenase-2 expression in carcinogenesis. We investigated the potential use of COX-2 inhibitors in cancer proliferation and apoptosis.
Reference:
Product link:
No comments:
Post a Comment